Asciminib hydrochloride

盐酸阿思尼布

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameAsciminib hydrochloride
Drug Alias Name阿西米尼AsciminibumAsciminibAsciminib hydrochlorideScemblix +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsSolid tumoursLeukemia, Myeloid, Chronic-PhaseBlast Crisis +[9] 
Global Approved IndicationsLeukemia, Myelogenous, Chronic
Approved Indications in ChinaLeukemia, Myelogenous, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2021/10/29
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[46] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteAugusta UniversityH Lee Moffitt Cancer Center & Research Institute +[12] 
Inactive CompaniesNovartis Pharma Schweiz AgBeijing Novartis Pharma Co Ltd
Active IndicationsSolid tumoursLeukemia, Myeloid, Chronic-PhaseBlast Crisis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG